Following the Money Trail: Where are Hedge Funds Investing?

In This Article:

For years, investors have chased the latest tech darlings, throwing money at overvalued companies based on hype and empty promises. At Insider Monkey we do things a little bit different. We focus our attention on not stock promoters but seasoned hedge fund managers and shrewd corporate insiders. We pay attention when informed executives and smart hedge fund managers are putting their money where their mouth is, buying up shares!

It isn't always straightforward to identify the smart insiders and hedge fund managers though. Periodically we go back in time and take a look at the predictions of hedge fund managers and evaluate the accuracy of these predictions. That's one of the ways we form an idea about the skill level of a particular hedge fund manager.

In this article, we will be exploring ten stocks that hedge funds were talking about 3-4 months ago. The S&P 500 Index ETF (SPY) returned about 10% over this period.

Three months ago we set aside several quarterly commentaries of hedge fund houses to select the stocks these hedge funds were bullish on. Virtu Financial (VIRT), PayPal Holdings, Inc. (PYPL), Jazz Pharmaceuticals (JAZZ), and Waters Corporation (NYSE:WAT) are some of the stocks listed in the article. We are going present these stocks based on their 2024 performance (from worst performing to best performing):

10. Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Number of hedge fund holdings at the end of Q3:40

2024 Return: -4.4%

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) is an Ireland based biopharmaceutical company. Pricing power, strong success track record, innovation and attractive valuation increases the popularity of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) among investors. Jazz Pharmaceuticals plc (NASDAQ:JAZZ), incorporated in 2003, is headquartered in Dublin, Ireland and has a market capitalization of $8.38 billion.

Aristotle Capital Global Equity Strategy made the following comment about Jazz Pharmaceuticals plc (NASDAQ:JAZZ) in its Q3 2023 investor letter:

"During the quarter, we sold our position in Magna International and invested in a new position, Jazz Pharmaceuticals plc (NASDAQ:JAZZ). Founded in 2003, Jazz Pharmaceuticals is a global biopharmaceutical company headquartered in Ireland. The drugmaker’s portfolio of nine approved products focuses on conditions with limited therapeutic treatments in neuroscience (~75% of 2022 revenue) and oncology (~25%).